Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13

References

• Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis. 1992;14(4):801–807. doi: 10.1093/clinids/14.4.801.
   PubMed Web of Science ®Google Scholar
• Dao TH, Rosch JW. JMM profile: Streptococcus pneumoniae: sugar-coated captain of the men of death. J Med Microbiol. 2021;70(11):001446. doi: 10.1099/jmm.0.001446.
   PubMed Web of Science ®Google Scholar
• King L. Advisory Committee on Immunization Practices. Pediatric outpatient ARI visits and antibiotic us attributable to serotypes in higher valency PCVs; 2023 [cited 2023 Mar 6]. Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2023-02/slides-02-22/Pneumococcal-03-King-508.pdf
   Google Scholar
• Ganaie F, Saad JS, McGee L, et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio. 2020;11(3):e00937-20. doi: 10.1128/mBio.00937-20.
   PubMed Web of Science ®Google Scholar
• U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent pneumococcal conjugate vaccine for infants and children. [Internet]. 2023 [updated 2023 Apr 27; cited 2023 Jun 14]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal
   Google Scholar
• Centers for Disease and Control Prevention. Advisory Committee on Immunization Practices (ACIP) recommendations; 2023 [updated 2023 Sep 22; cited 2023 Oct 9]. Available from: https://www.cdc.gov/vaccines/acip/recommendations.html
   Google Scholar
• Cohen R, Levy C, Ouldali N, et al. Invasive disease potential of pneumococcal serotypes in children after PCV13 implementation. Clin Infect Dis. 2021;72(8):1453–1456. doi: 10.1093/cid/ciaa917.
   PubMed Web of Science ®Google Scholar
• Tomczyk S, Lynfield R, Schaffner W, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–1125. doi: 10.1093/cid/ciw067.
   PubMed Web of Science ®Google Scholar
• Harboe ZB, Thomsen RW, Riis A, et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLOS Med. 2009;6(5):e1000081. doi: 10.1371/journal.pmed.1000081.
   PubMed Web of Science ®Google Scholar
• Oligbu G, Collins S, Sheppard CL, et al. Childhood deaths attributable to invasive pneumococcal disease in England and Wales, 2006–2014. Clin Infect Dis. 2017;65(2):308–314. doi: 10.1093/cid/cix310.
   PubMed Web of Science ®Google Scholar
• Cui YA, Patel H, O'Neil WM, et al. Pneumococcal serotype distribution: a snapshot of recent data in pediatric and adult populations around the world. Hum Vaccin Immunother. 2017;13(6):1–13.
   Web of Science ®Google Scholar
• Balsells E, Guillot L, Nair H, et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLOS One. 2017;12(5):e0177113. doi: 10.1371/journal.pone.0177113.
   PubMed Web of Science ®Google Scholar
• Hausdorff WP, Hanage WP. Interim results of an ecological experiment – conjugate vaccination against the pneumococcus and serotype replacement. Hum Vaccin Immunother. 2016;12(2):358–374. doi: 10.1080/21645515.2015.1118593.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control Prevention. Invasive pneumococcal disease and 13-valent pneumococcal conjugate vaccine (PCV13) coverage among children aged ≤59 months–selected US regions, 2010–2011. MMWR Morb Mortal Wkly Rep. 2011;60(43):1477–1481.
   PubMedGoogle Scholar
• Flasche S, Lipsitch M, Ojal J, et al. Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study. BMC Med. 2020;18(1):129. doi: 10.1186/s12916-020-01601-1.
   PubMed Web of Science ®Google Scholar
• Sigurdsson S, Erlendsdóttir H, Quirk SJ, et al. Pneumococcal vaccination: direct and herd effect on carriage of vaccine types and antibiotic resistance in Icelandic children. Vaccine. 2017;35(39):5242–5248. doi: 10.1016/j.vaccine.2017.08.020.
   PubMed Web of Science ®Google Scholar
• Weinberger DM, Pitzer VE, Regev-Yochay G, et al. Association between the decline in pneumococcal disease in unimmunized adults and vaccine-derived protection against colonization in toddlers and preschool-aged children. Am J Epidemiol. 2019;188(1):160–168. doi: 10.1093/aje/kwy219.
   PubMed Web of Science ®Google Scholar
• Kobayashi M. Pneumococcal Vaccines Work Group considerations and next steps; 2022.
   Google Scholar
• Centers for Disease Control and Prevention. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices (ACIP); 2019 [updated 2019 Oct 11; cited 2021 Dec]. Available from: https://www.cdc.gov/vaccines/acip/committee/downloads/Economics-Guidance-for-ACIP-2019.pdf
   Google Scholar
• US Census Bureau. National demographic analysis tables 2020; 2021 [cited 2022 Nov 17]. Available from: https://www.census.gov/data/tables/2020/demo/popest/2020-demographic-analysis-tables.html
   Google Scholar
• US Census Bureau. Total U.S. resident population by age, sex, and series; 2020 (in thousands).
   Google Scholar
• Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Streptococcus pneumoniae, 2019; 2019 [cited 2022 Nov 17]. Available from: www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf
   Google Scholar
• Stoecker C, editor. Economic assessment of PCV15 & PCV20. Atlanta (GA): Advisory Committee on Immunization Practices Meeting; 2021.
   Google Scholar
• Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373(5):415–427. doi: 10.1056/NEJMoa1500245.
   PubMed Web of Science ®Google Scholar
• Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812. doi: 10.1093/cid/cix647.
   PubMed Web of Science ®Google Scholar
• Tong S, Amand C, Kieffer A, et al. Trends in healthcare utilization and costs associated with acute otitis media in the United States during 2008–2014. BMC Health Serv Res. 2018;18(1):318. doi: 10.1186/s12913-018-3139-1.
   PubMed Web of Science ®Google Scholar
• Averin A, Shaff M, Weycker D, et al. Mortality and readmission in the year following hospitalization for pneumonia among US adults. Respir Med. 2021;185:106476. doi: 10.1016/j.rmed.2021.106476.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Farrar JL, Gierke R, et al. Use of 15-valent pneumococcal conjugate vaccine among U.S. children: updated recommendations of the Advisory Committee on Immunization Practices – United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–117. doi: 10.15585/mmwr.mm7104a1.
   PubMed Web of Science ®Google Scholar
• Rubin JL, McGarry LJ, Strutton DR, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634–7643. doi: 10.1016/j.vaccine.2010.09.049.
   PubMed Web of Science ®Google Scholar
• Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460–1468. doi: 10.1001/jama.283.11.1460.
   PubMed Web of Science ®Google Scholar
• Shepard CW, Ortega-Sanchez IR, Scott RD, et al. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Pediatrics. 2005;115(5):1220–1232. doi: 10.1542/peds.2004-2514.
   PubMed Web of Science ®Google Scholar
• Hill HA, Chen M, Elam-Evans LD, et al. Vaccination coverage by age 24 months among children born during 2018–2019—national immunization survey–child, United States, 2019–2021. MMWR Morb Mortal Wkly Rep. 2023;72(2):33–38. doi: 10.15585/mmwr.mm7202a3.
   PubMed Web of Science ®Google Scholar
• Moore MR, Link-Gelles R, Schaffner W, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. doi: 10.1016/S2213-2600(16)00052-7.
   PubMed Web of Science ®Google Scholar
• Savulescu C, Krizova P, Valentiner-Branth P, et al. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: spIDnet observational multicentre study. Vaccine. 2022;40(29):3963–3974. doi: 10.1016/j.vaccine.2022.05.011.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Gessner BD, Fung S, et al. Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011–2016. Vaccine. 2018;36(49):7479–7486. doi: 10.1016/j.vaccine.2018.10.060.
   PubMed Web of Science ®Google Scholar
• Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using world health organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25(9):779–781. doi: 10.1097/01.inf.0000232706.35674.2f.
   PubMed Web of Science ®Google Scholar
• Black SB, Shinefield HR, Ling S, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J. 2002;21(9):810–815. doi: 10.1097/00006454-200209000-00005.
   PubMed Web of Science ®Google Scholar
• Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–195. doi: 10.1097/00006454-200003000-00003.
   PubMed Web of Science ®Google Scholar
• Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media-related health care use in the United States, 2001–2011. JAMA Pediatr. 2014;168(1):68–75. doi: 10.1001/jamapediatrics.2013.3924.
   PubMed Web of Science ®Google Scholar
• Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017;5(1):e51–e59. doi: 10.1016/S2214-109X(16)30306-0.
   PubMed Web of Science ®Google Scholar
• Ben-Shimol S, Givon-Lavi N, Leibovitz E, et al. Impact of widespread introduction of pneumococcal conjugate vaccines on pneumococcal and nonpneumococcal otitis media. Clin Infect Dis. 2016;63(5):611–618. doi: 10.1093/cid/ciw347.
   PubMed Web of Science ®Google Scholar
• Gentile A, Bakir J, Firpo V, et al. PCV13 vaccination impact: a multicenter study of pneumonia in 10 pediatric hospitals in Argentina. PLOS One. 2018;13(7):e0199989. doi: 10.1371/journal.pone.0199989.
   PubMed Web of Science ®Google Scholar
• Greenberg D, Givon-Lavi N, Ben-Shimol S, et al. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years. Vaccine. 2015;33(36):4623–4629. doi: 10.1016/j.vaccine.2015.06.062.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Active bacterial core surveillance: trends by serotype group; 2018 [cited 2022 Nov 17]. Available from: https://www.cdc.gov/abcs/reports-findings/survreports/spneu-types.html
   Google Scholar
• Pfizer. ABCs confidential serotype-specific data file for the years 2000–2018.
   Google Scholar
• Weycker D, Moynahan A, Silvia A, et al. Attributable cost of adult hospitalized pneumonia beyond the acute phase. Pharmacoecon Open. 2021;5(2):275–284. doi: 10.1007/s41669-020-00240-9.
   PubMed Web of Science ®Google Scholar
• Weycker D, Farkouh RA, Strutton DR, et al. Rates and costs of invasive pneumococcal disease and pneumonia in persons with underlying medical conditions. BMC Health Serv Res. 2016;16(1):182. doi: 10.1186/s12913-016-1432-4.
   PubMed Web of Science ®Google Scholar
• King LM, Andrejko KL, Kabbani S, et al. Pediatric outpatient visits and antibiotic use attributable to higher valency pneumococcal conjugate vaccine serotypes. medRxiv. 2023:2023.08.24.23294570.
   Google Scholar
• Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–816. doi: 10.1007/s11136-020-02650-y.
   PubMed Web of Science ®Google Scholar
• Stoecker C, Hampton LM, Link-Gelles R, et al. Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine. Pediatrics. 2013;132(2):e324–e332. doi: 10.1542/peds.2012-3350.
   PubMed Web of Science ®Google Scholar
• Melegaro A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine. 2004;22(31–32):4203–4214. doi: 10.1016/j.vaccine.2004.05.003.
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, van Hoek AJ, Fleming D, et al. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ. 2012;345(1):e6879. doi: 10.1136/bmj.e6879.
   PubMedGoogle Scholar
• Mangen MJ, Huijts SM, Bonten MJ, et al. The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect Dis. 2017;17(1):208. doi: 10.1186/s12879-017-2302-3.
   PubMed Web of Science ®Google Scholar
• Mangen MJ, Rozenbaum MH, Huijts SM, et al. Cost-effectiveness of adult pneumococcal conjugate vaccination in The Netherlands. Eur Respir J. 2015;46(5):1407–1416. doi: 10.1183/13993003.00325-2015.
   PubMed Web of Science ®Google Scholar
• Oostenbrink R, Moll HA, Essink-Bot M-L. The EQ-5D and the health utilities index for permanent sequelae after meningitis: a head-to-head comparison. J Clin Epidemiol. 2002;55(8):791–799. doi: 10.1016/s0895-4356(02)00448-1.
   PubMed Web of Science ®Google Scholar
• Erickson LJ, De Wals P, McMahon J, et al. Complications of meningococcal disease in college students. Clin Infect Dis. 2001;33(5):737–739. doi: 10.1086/322587.
   PubMed Web of Science ®Google Scholar
• Pfizer. Prenar 20 (pneumococcal 20-valent conjugate vaccine), suspension for intramuscular injection, prescribing information; 2021.
   Google Scholar
• Strutton DR, Farkouh RA, Rubin JL, et al. Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis. 2012;12(1):175. doi: 10.1186/1471-2334-12-175.
   PubMedGoogle Scholar
• Flasche S, Ojal J, Le Polain de Waroux O, et al. Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya. BMC Med. 2017;15(1):113. doi: 10.1186/s12916-017-0882-9.
   PubMed Web of Science ®Google Scholar
• Centers for Disease and Control Prevention. Pneumococcal disease; 2020 [updated 2020 Sep 1; cited 2023 Jul 11]. Available from: https://www.cdc.gov/pneumococcal/about/diagnosis-treatment.html
   Google Scholar
• Murray CJ, Ikuta KS, Sharara F, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. doi: 10.1016/S0140-6736(21)02724-0.
   PubMed Web of Science ®Google Scholar
• Centers for Disease and Control Prevention. Antibiotic resistance threats in the United States, 2019; 2019 [cited 2023 Mar 6]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
   Google Scholar
• Klugman KP, Black S. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects. Proc Natl Acad Sci USA. 2018;115(51):12896–12901. doi: 10.1073/pnas.1721095115.
   PubMed Web of Science ®Google Scholar
• Mohanty S, Feemster K, Yu KC, et al. Trends in Streptococcus pneumoniae antimicrobial resistance in US children: a multicenter evaluation. Open Forum Infect Dis. 2023;10(3):ofad098. doi: 10.1093/ofid/ofad098.
   PubMed Web of Science ®Google Scholar
• Buchy P, Ascioglu S, Buisson Y, et al. Impact of vaccines on antimicrobial resistance. Int J Infect Dis. 2020;90:188–196. doi: 10.1016/j.ijid.2019.10.005.
   PubMed Web of Science ®Google Scholar
• Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet. 2006;368(9546):1495–1502. doi: 10.1016/S0140-6736(06)69637-2.
   PubMed Web of Science ®Google Scholar
• Rozenbaum MH, Sanders EA, van Hoek AJ, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010;340(1):c2509. doi: 10.1136/bmj.c2509.
   PubMedGoogle Scholar
• Strutton DR, Farkouh RA, Earnshaw SR, et al. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. J Infect. 2012;64(1):54–67. doi: 10.1016/j.jinf.2011.10.015.
   PubMed Web of Science ®Google Scholar
• Centers for Disease and Control Prevention. AR threats report; 2019 [cited 2023 Mar 21]. Available from: https://www.cdc.gov/drugresistance/biggest-threats.html
   Google Scholar
• Huang M, Hu T, Weaver J, et al. Cost-effectiveness analysis of routine use of 15-valent pneumococcal conjugate vaccine in the US pediatric population. Vaccines. 2023;11(1):135. doi: 10.3390/vaccines11010135.
   Web of Science ®Google Scholar